| 000 | 01364 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250513033515.0 | ||
| 264 | 0 | _c19951124 | |
| 008 | 199511s 0 0 eng d | ||
| 022 | _a0022-510X | ||
| 024 | 7 |
_a10.1016/0022-510x(95)00051-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSmith, R A | |
| 245 | 0 | 0 |
_aPharmacokinetics and tolerability of ventricularly administered superoxide dismutase in monkeys and preliminary clinical observations in familial ALS. _h[electronic resource] |
| 260 |
_bJournal of the neurological sciences _cMay 1995 |
||
| 300 |
_a13-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAmyotrophic Lateral Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntioxidants _xadverse effects |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intraventricular |
| 650 | 0 | 4 | _aMacaca mulatta |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuscles _xphysiopathology |
| 650 | 0 | 4 |
_aSuperoxide Dismutase _xadverse effects |
| 700 | 1 | _aBalis, F M | |
| 700 | 1 | _aOtt, K H | |
| 700 | 1 | _aElsberry, D D | |
| 700 | 1 | _aSherman, M R | |
| 700 | 1 | _aSaifer, M G | |
| 773 | 0 |
_tJournal of the neurological sciences _gvol. 129 Suppl _gp. 13-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0022-510x(95)00051-3 _zAvailable from publisher's website |
| 999 |
_c7595043 _d7595043 |
||